OPKO Health Inc. (OPK) News Headlines

▮ More

Date

Headline

10/7/2019 6:36:13 AM 5 Healthcare Stocks Facing Key Catalysts In Q4, 2019

8/29/2019 9:51:03 AM OPKO Completes Pivotal Phase 3 Study For Somatrogon

7/1/2019 8:06:10 AM BioReference Laboratories Forms Strategic Collaboration With SOMOS To Improve Health Outcomes Of Underserved New Yorkers

2/5/2019 8:35:08 AM OPKO Health Reports Pricing Of Offering Of $200 Mln Convertible Senior Notes Due 2025

2/1/2019 8:09:52 AM OPKO Health Gets FDA Approval For Point-of-Care Sangia PSA Test With Claros 1 Analyzer

2/1/2019 12:12:48 AM AVEO Crashes, FDA Approves 1st Generic Of ADVAIR DISKUS, 'Tis Advantage TTNP

1/31/2019 9:17:01 PM OPKO Provides Update On Development Of OPK-88004, Selective Androgen Receptor Modulator

1/7/2019 6:04:24 AM OPKO Health Appoints Jon Cohen As Executive Chairman Of BioReference Laboratories

11/12/2018 9:05:09 PM OPK To Report Data In Q1, EIDX Cheers Investors, Busy Year Ahead For VRCA

11/9/2018 4:57:55 PM OPKO Health Q3 Loss Per Share $0.05 Vs. $0.06 Last Year

9/12/2018 2:28:34 AM FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct.

9/11/2018 8:32:46 AM OPKO Comments On Continued Nasdaq Halt Of Trading Of Common Stock

9/7/2018 3:42:03 PM Nasdaq Halts OPKO Health

9/5/2018 3:51:54 AM BCRX At Its Zenith, CRON Walks The Walk, TSRO To Report Data In Nov.

6/11/2018 8:08:59 AM OPKO Health Completes Enrollment In Phase 2b Study Of OPK88003 To Treat Type 2 Diabetes And Obesity

5/9/2018 8:54:36 PM OPK Up 36% In 5 Days, SLDB Sparkles, CERS Abuzz, ARWR Expects Data In Nov.

3/23/2018 8:01:41 AM OPKO Health Enrolls First Patient In Phase 2b Study Of OPK88003 To Treat Type 2 Diabetes

1/19/2018 7:58:33 AM A Rundown Of Dravet Syndrome Drugs In The Pipeline

6/21/2016 2:34:10 AM OPKO Health Says FDA Approves NDA For RAYALDEE

Older Articles

Opko Health Inc. (OPK)